Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 3/20 | 0.36 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HINT1 | P49773 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | INMT | O95050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL882148 | 0.91 | DCPS (0.42) | DCPSTMPRSS2HINT1MAPTINMT | |
| SCHEMBL882461 | 0.89 | DCPS (0.35) | DCPSTMPRSS2HINT1MAPT | |
| SCHEMBL18697917 | 0.88 | DCPS (0.35) | DCPSTACR1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL10184151 | 0.87 | DCPS (0.36) | DCPSTACR1ALDH1A1MAPTINMT | |
| SCHEMBL14996130 | 0.87 | DCPS (0.36) | DCPSTACR1ALDH1A1MAPTINMT | |
| SCHEMBL18697875 | 0.81 | DCPS (0.42) | DCPSHINT1INMT | |
| SCHEMBL12465037 | 0.80 | DCPS (0.35) | DCPSALDH1A1HINT1MAPTINMT | |
| SCHEMBL18214643 | 0.78 | DCPS (0.34) | DCPS | |
| SCHEMBL10183545 | 0.78 | DCPS (0.41) | DCPSHINT1MAPTINMT | |
| SCHEMBL18697904 | 0.76 | TMPRSS2 (0.43) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012039787-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-03-29 | — | — | WO | disclosed |